Заар 100 мг капсулы

Land: Kirgizistan

Språk: ryska

Källa: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Aktiva substanser:

Прегабалин

Tillgänglig från:

Wilshire Laboratories (Pvt.) Ltd. (Wilshire Laboratories (Pvt.) Ltd.)

ATC-kod:

N03AX16

INN (International namn):

Pregabalin

Dos:

100 мг

Läkemedelsform:

капсулы

Enheter i paketet:

№20

Receptbelagda typ:

по рецепту

Tillverkad av:

Wilshire Laboratories (Pvt.) Ltd. (Пакистан)

Produktsammanfattning:

ПЖВЛС: нет

Tillstånd datum:

2019-03-05

Produktens egenskaper

YTBEPKAAIO
3
KTOpa
,[enapraue
o6ecue'Ieu[g
u
Musr.t
Ku
.[xau
IIHCTPYKII}Ifl
TI
O
MEALIUI'IH
CK
OMY
TIPI'IMEHEHI'IIO
JIEKAP
CTBEHH
OI
O
TIPETIAPATA
3AAP
Topronoe
Ha3BaHIre
3AAP
MexgyrrapoAHoe
HerIareHToBaHHoe
Ha3BaIIlle
flpera6a,rnu
JlerapcrneHHaq
{oPna
Kaucymt
Cocras
I
xancyla
coAepxo,Ir
Arcmtterrozo
ileulecntsa
-
upera6a,rrasa
50,00
ltr,
75,00
vrr,
100,00
rvrr;
BcnouozamerbHde
Geulecm1a.'
JIaKTo3bI
MoHorHApaT,
KpaxMaJt
KyKypy3Hblfi,
ranx;
COChC1T
O,OnOuxu
mCepdOit
)rceflam\HoeOil
xAnCytbr.'
XeJIaTI'IH,
BOAa
OqHtUeHHag',
Tr4TaHa
Ar4oKcrrA
G,
171),
Nelesa
oKcI4A
xpaffruil
(E
172),
Harpvrfl'
naypl4ncynr@ar,
KpeMHLIq
AI4oK0I4A
KoJrnoHAHbIfi
6egsoAurtfi
,
Cocmaa
qepHbtx
LtepHuI
SW-g008/-9009:
uIeJIJIaK,
xeJle3a
oKcLIA
uepuslfi
(E
172)'
IIponI{neHfJII4KOJIb,
KaJII4s
fI{ApoKcI4A.
Ouucauue
Eelrrfi
roporxo1
3arroJrHeH
B
KancynbHyo
o6olouxy
c
6enofi
rpuurxofi
u
6elsur'l
KopnycoM'
@apuaxorepa[eBTlrrrecKaq
rpyflrra
flpenaparu
Ins
Jrer{eHr.rs
:a6oreeanufi
uepauofi
cl{creMbl
flporanosnl4nelIrHqecKl{e
,p"nupurur.
llporunosrr.rJrerrrlrlrecKHe
nperaparbr
Apyrue.
flpera6arutu.
Koa
ATX
N03AX16
KII
h'
ttn
{Dapmaro,'toruqecxlle
cnoiicrna
@apuarcoxuHemuKa
Oapuarcoxnuerl'IqecKl4e
noxa3arelu
npera6arlrHa
B
3AopoBblx
lro4efi,
y
nauueHToB
c
anulelcueii,
npeuaparbl,
14
y
rlau[eHToB
c
xpoHl4r{ecKofr
6ollro.
Bcacuaauue
Ilpera6a:rrau
6rtcrpo
BcacblBaercfl
HarolrlaK.
Kouqenrp]
AOCTHfaeT
nI,IKa
rlepe3
oALIH
qac,
KaK
npl4
OAHOKpaTHOM,
Buo4ocrynHocrb
[pera6aJll4Ha
rlpu
npl4eMe
BHyrpb
coc
rpuurrofi
Ao3bI.
IIpu
noBTopHoM
[pI{MeHeHI'Iu
paB
rerreHae
24-48
qacoB.
Ilpuelt
ilktu\u
yxyAlxaer
BcacblBl
paBHoBecHoM
COCTO.SHI,
H
AHUtOrI4r{HbI
y
rlufl
npenapaTa
B
[JIa3Me
KpoBpI
TaK
I,I
MHOIOKpaTHOM
rIpI'IMeHeHHI4.
aBJIser
>
90
%
u
He
3aBI4cI'Ir
or
oBecHoe
cocroqHue
Aocrlrfaercf,
B
Hr,re
rpera6aturta.
flptl
orou
C*a*
MaKcuManbsofi
ronueutpauuu
(tmax)
cHr.rxaercfl
npl{MepHo
sa
25-30
Yo,
a
spevrl
AocrH}I(eHI'L
yBenr.rtr[BaeTcs
upu6JII,I3LITeJIbH
o
[o
2,5
q.
OAsarO,
np]IMegeHue
upera6glgna
C
Uuulefi
He
OKA3bIBAET
KII,IHI/IIIECKI,I
3HAAI}IMOTO
BJI}ISHI'Ifl
HA
CTE